Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Nguyen Ngoc

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Nuklearmedizin. Nuclear Medicine|February 16, 2019
Christina Nguyen Ngoc, Christian Happel, Amir Sabet, et al.
Clinical Case Reports|May 8, 2023
Thyroid papillary cancer elements arising from struma ovarii with benign peritoneal strumosis: Utility of iodine-123 imaging in diagnostics and treatment planningDaniel Groener, Justus Baumgarten, Christian Happel, et al.
Plos One|November 19, 2013
High calcium bioglass enhances differentiation and survival of endothelial progenitor cells, inducing early vascularization in critical size bone defectsKaram Eldesoqi, Caroline Seebach, Christina Nguyen Ngoc, et al.
Nuklearmedizin. Nuclear Medicine|February 16, 2022
[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 26, 2023
Extended therapy with [<sup>177</sup>Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancerNicolai Mader, Christina Nguyen Ngoc, Bilge Kirkgöze, et al.
Cancers|August 27, 2021
Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow InvolvementDaniel Groener, Justus Baumgarten, Sebastian Haefele, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
Cancers|February 15, 2022
Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-DichlorideJustus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, et al.
Cancers|August 12, 2023
Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CTDaniel Groener, Jennifer Wichert, Magdalena Adams, et al.
EJNMMI Research|July 3, 2021
Hematologic safety of <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancerDaniel Groener, Cam Tu Nguyen, Justus Baumgarten, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nuklearmedizin. Nuclear Medicine|February 16, 2019
Christina Nguyen Ngoc, Christian Happel, Amir Sabet, et al.
Clinical Case Reports|May 8, 2023
Thyroid papillary cancer elements arising from struma ovarii with benign peritoneal strumosis: Utility of iodine-123 imaging in diagnostics and treatment planningDaniel Groener, Justus Baumgarten, Christian Happel, et al.
Plos One|November 19, 2013
High calcium bioglass enhances differentiation and survival of endothelial progenitor cells, inducing early vascularization in critical size bone defectsKaram Eldesoqi, Caroline Seebach, Christina Nguyen Ngoc, et al.
Nuklearmedizin. Nuclear Medicine|February 16, 2022
[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 26, 2023
Extended therapy with [<sup>177</sup>Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancerNicolai Mader, Christina Nguyen Ngoc, Bilge Kirkgöze, et al.
Cancers|August 27, 2021
Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow InvolvementDaniel Groener, Justus Baumgarten, Sebastian Haefele, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
Cancers|February 15, 2022
Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-DichlorideJustus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, et al.
Cancers|August 12, 2023
Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CTDaniel Groener, Jennifer Wichert, Magdalena Adams, et al.
EJNMMI Research|July 3, 2021
Hematologic safety of <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancerDaniel Groener, Cam Tu Nguyen, Justus Baumgarten, et al.
Pageof 1